Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 15, 2026 08:00 ET | Source: Achieve Life Sciences

Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions

Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial Launch Expected in First Half of 2027 ...
April 15, 2026 07:25 ET | Source: ALTERITY THERAPEUTICS LIMITED

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

MELBOURNE, Australia and SAN FRANCISCO, April 15, 2026 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to...
April 15, 2026 07:00 ET | Source: Beeline Medicines Corporation

Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases – – Lead program afimetoran, a potential...
April 15, 2026 07:00 ET | Source: Tonix Pharmaceuticals Holding Corp.

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

TONMYA (cyclobenzaprine HCl sublingual tablets) for long-term daily dosing at bedtime, is the first new FDA-approved treatment for fibromyalgia in adults in more than 15 years TONMYA commercially...
April 15, 2026 01:00 ET | Source: BioVersys

BioVersys to Present Data on Clinical and Preclinical Pipeline Programs at ESCMID Global 2026

BASEL, Switzerland, April 15, 2026 (GLOBE NEWSWIRE) -- Poster presentations to feature data from clinical asset BV100 addressing carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex...
April 14, 2026 17:15 ET | Source: Pomerantz LLP

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc. - PEPG

NEW YORK, April 14, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PepGen Inc. (“PepGen” or the “Company”) (NASDAQ: PEPG). Such investors are advised to...
April 14, 2026 16:05 ET | Source: Aligos Therapeutics

Aligos Therapeutics Announces First Interim Analysis Results from the Phase 2 B-SUPREME Study of Pevifoscorvir Sodium in Participants with Chronic Hepatitis B Virus Infection and Grant of FDA Fast Track Designation

Received FDA Fast Track Designation for pevifoscorvir sodium for the treatment of chronic hepatitis B virus infectionHBeAg- cohort sample size increased to optimize powering; futility criteria not...
April 14, 2026 14:08 ET | Source: Galera Therapeutics

Galera Therapeutics and Obsidian Therapeutics Announce Merger Agreement and $350 Million Concurrent Private Placement

Combined company to operate as Obsidian Therapeutics, Inc. and to advance Obsidian’s pipeline of novel engineered TIL cell therapies for the treatment of patients with solid tumors.Obsidian’s lead...
April 14, 2026 09:00 ET | Source: Merakris Therapeutics

Merakris Therapeutics and iFyber Collaboration Receives Top SAWC Research Award for MTX-001 Wound Healing Study in Human Skin Model

Merakris’ MTX-001 research wins SAWC award; human data show significant wound healing. Phase 2 ongoing with FDA and manufacturing catalysts ahead.
April 14, 2026 09:00 ET | Source: NeOnc Technologies Holdings, Inc.

NeOnc Technologies Holdings, Inc. Announces ~ $300,000 in Insider Purchases of NTHI Stock by Chairman and CEO; Company Provides Context on 2025 Financial Results

Insider buying indicates management's conviction in undervalued shares ahead of multiple near-term catalysts: NEO100: interim data readout - expected within ~4 months NEO212: expects Type B...